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Abstract
Acute myeloid leukaemia (AML) comprises a heterogeneous group of hematologic
neoplasms characterized by diverse combinations of genetic, phenotypic and clinical
features representing a major challenge for the development of targeted therapies.
Metabolic reprogramming, mainly driven by deregulation of the nutrient-sensing
pathways as AMPK, mTOR and PI3K/AKT, has been associated with cancer cells,
including AML cells, survival and proliferation. Nevertheless, the role of these meta-
bolic adaptations on the AML pathogenesis is still controversial. In this work, the
metabolic status and the respective metabolic networks operating in different AML
cells (NB-4, HL-60 and KG-1) and their impact on autophagy and survival was char-
acterized. Data show that whereas KG-1 cells exhibited preferential mitochondrial
oxidative phosphorylation metabolism with constitutive co-activation of AMPK and
mTORC1 associated with increased autophagy, NB-4 and HL-60 cells displayed a
dependent glycolytic profile mainly associated with AKT/mTORC1 activation and
low autophagy flux. Inhibition of AKT is disclosed as a promising therapeutical tar-
get in some scenarios while inhibition of AMPK and mTORC1 has no major impact
on KG-1 cells’ survival. The results highlight an exclusive metabolic profile for each
tested AML cells and its impact on determination of the anti-leukaemia efficacy and
on personalized combinatory therapy with conventional and targeted agents.
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1 | INTRODUCTION
Acute myeloid leukaemia (AML) comprises a group of heterogeneous
hematopoietic disorders characterized by a multitude of genetic/epi-
genetic aberrations, altered differentiation, proliferation and self-
renewal of hematopoietic stem cells and myeloid progenitors.1-3
AML intensive chemotherapy regimens have favourable outcomes in
young patients4 but limited application and poor outcomes among
elderly, the most affected population.5-7 Given the genetic, pheno-
typic and clinical diversity among the AML patients, the development
of targeted therapies remains a major challenge.8 Therefore, the elu-
cidation of the mechanisms underlying the multi-stages and multi-
causal pathogenesis of AML is demanding.
A switch from mitochondrial oxidative phosphorylation
(OXPHOS) to glycolytic metabolism, recognized as “Warburg effect,”
is a common strategy used by cancer cells to overcome their
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bioenergetics needs.9,10 This metabolic reprogramming provides
tumour cells with advantages necessary for sustaining their high pro-
liferation rates, such as the rapid generation of ATP and intermedi-
ates for the synthesis of fatty acids, nucleotides and amino acids.11
Studies in AML cell lines and human primary AML blasts correlated
metabolic reprogramming with chemo-resistance showing that
enhanced glycolysis decreases the AML cells sensitivity to cytara-
bine, while the inhibition of glycolysis potentiates the cytotoxicity of
this anti-leukaemia agent.12 Furthermore, it was also proposed that
the extent of myeloblast glycolysis may be an effective method to
determine the pretreatment prognosis of AML.13
Importantly, the metabolic reprogramming in cancer cells is
mainly associated with the deregulation of the major nutrient-sen-
sing pathways: the AMP-activated protein kinase (AMPK), the mam-
malian target of rapamycin complex 1 (mTORC1) and the
phosphoinositide 3-kinase (PI3K)/serine/threonine protein kinase B
(AKT).14 Deregulation of these signalling pathways, which enhance
cellular survival and proliferation, seems to cooperate with genetic
abnormalities to the pathogenesis of AML.15 In fact, while PI3K/AKT
pathway is often found activated in AML, mTORC1 appears to be
active in all reported AML cases.16,17 Both mTORC1 and AKT seem
to contribute for the glycolytic metabolism of some AML cells and
human primary AML blasts.18,19 Globally, it is still debatable and con-
troversial if the deregulation of AMPK, mTORC1 and/or AKT in
AML cells would function as a tumour suppressor or pro-
moter.15,17,20-26 Nevertheless, once activated, AMPK27-29 and
AKT29,30 may control macroautophagy in mTORC1-(in)dependent
pathway(s). Macroautophagy, hereafter referred as to autophagy, is a
multi-step self-degradative process by which cytoplasmic content,
such as long-lived proteins and superfluous/damaged organelles, is
delivered to lysosomes for degradation.31 Deregulation of autophagy
has been extensively described in AML acting both as tumour pro-
moting and suppressing.26,32-34 Therefore, the elucidation of the
interconnection between the nutrient-sensing players, autophagy
and energetic metabolism is of major relevance to understand cellu-
lar homeostasis and survival of AML cells. Herein, results provide
evidence that different AML cells present diverse metabolic profiles.
Indeed, whereas KG-1 cells exhibited preferential OXPHOS metabo-
lism with co-activation of AMPK and mTORC1 associated with
increased autophagy flux, NB-4 and HL-60 cells displayed high intra-
cellular ATP levels and a glycolytic profile mainly associated with
AKT/mTORC1 activation and low autophagy flux. Inhibition of AKT
is disclosed as a promising target for therapeutic intervention in
some scenarios while inhibition of AMPK and mTORC1 has no major
impact on KG-1 cells survival.
2 | MATERIAL AND METHODS
2.1 | Cell culture
The NB-4, HL-60 and KG-1 cell lines were obtained from the German
Collection of Microorganisms and Cell cultures (DSMZ - Deutsche
Sammlung von Mikroorganismen und Zellkulturen—German). The cells
were maintained in RPMI 1640 medium (Biochrom) supplemented
with 10% heat-inactivated fetal bovine serum (FBS; Biochrom) and
1% antibiotic-antimycotic solution (Invitrogen) in a humidified, 37°C,
5% CO2 atmosphere.
2.2 | Treatments
Compound C (CC) was purchased from Sigma-Aldrich and dissolved
in dH2O. Rapamycin (Rap) and bafilomycin A1 were also obtained
from Sigma-Aldrich but dissolved in DMSO. MK-2206 was pur-
chased from Bertin Pharma and prepared in DMSO. Final concen-
tration of compounds: CC—2.5 lmol/L; Rap—2 lmol/L, bafilomycin
A1—10 nmol/L; MK-2206—20 lmol/L.
NB-4 and HL-60 cells were submitted to MK-2206, while KG-1
cells were exposed to CC or Rap. All tested AML cells were treated
with bafilomycin A1 for the assessment of autophagy flux. To study
the glycolytic metabolism dependence, AML cells were cultured for
24 hours in RPMI 1640 medium depleted of glucose (Alfagene)
supplemented with 10% heat-inactivated FBS (Biochrom), 1%
antibiotic-antimycotic solution (Invitrogen) and 11 mmol/L 2-
Deoxy-D-glucose (2-DG; Sigma-Aldrich) in a humidified, 37°C, 5%
CO2 atmosphere.
2.3 | Determination of the extracellular glucose and
lactate levels
NB-4, HL-60 and KG-1 cells were plated at 0.5 9 106 cells/mL/well,
cultured for 24 hours with or without the respective treatment(s),
collected and the supernatant reserved. Measurement of the extra-
cellular glucose and lactate levels was performed using the glucose
test kit from R-Biopharm and the lactate test kit from Spinreact
according to the manufacturer’s instructions. At least, 3 independent
biological replicates were performed.
2.4 | Quantification of the intracellular ATP levels
NB-4, HL-60 and KG-1 cells were plated at 0.5 9 106 cells/mL/well,
cultured for 24 hours, collected and the pellet reserved. Intracellular
ATP levels were determined using the ENLITEN ATP Assay System
from Promega according to the manufacturer’s instructions. At
least, 3 independent biological replicates were performed.
2.5 | Measurement of cell viability—Annexin V/PI
assay
NB-4, HL-60 and KG-1 cells were plated at 0.5 9 106 cells/mL/well,
cultured for 24 hours with or without the respective treatment(s)
and collected. The cells were then washed with 800 lL of phos-
phate-buffered saline (PBS) followed by the addition of 100 lL of
binding buffer to each sample. An incubation with 5 lL of annexin V
(BD Biosciences) and 10 lL of propidium iodide (PI) at 50 lg/mL
(Invitrogen) was then performed for 15 minutes at room tempera-
ture in the dark. Two hundred microlitres of binding buffer was
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added once again to each sample. PI signal was measured using the
FACS LSRII flow cytometer (BD Biosciences) with a 488-nm excita-
tion laser. The annexin V signal was collected through a 488-nm
blocking filter, a 550-nm long-pass dichroic with a 525-nm band
pass. Signals from 10 000 cells/sample were captured, and FACS
Diva was used as the acquisition software. Analysis of the results
was performed using the FlowJo 7.6 (Tree Star) software. At least,
3 independent biological replicates were performed.
2.6 | Immunoblotting analysis
Protein extraction from NB-4, HL-60 and KG-1 cells upon 24 hours
of culture with or without the respective treatment(s) (0.5 9 106
cells/mL/well were plated) was performed with 100 lL of lysis buf-
fer (1% NP-40; 500 mmol/L Tris-HCL, 2.5 mol/L NaCl, 20 mmol/L
EDTA, phosphatase and protease inhibitors (Roche); pH 7.2).
Twenty micrograms of the total protein was resolved in a 12%
sodium dodecyl sulphate (SDS) polyacrylamide gel and transferred to
a nitrocellulose membrane for 7 or 12 minutes in the Trans-Blot
Turbo Transfer System (Bio-Rad). Membranes were blocked for
1 hour in tris-buffered saline (TBS) with 0.1% Tween-20 (TBS-T)
containing 5% bovine serum albumin (BSA; Sigma-Aldrich) and
afterwards incubated overnight at 4°C with the polyclonal primary
antibodies at 1:1000 in 1% BSA—rabbit anti-phospho-AMPKa
(Thr172) antibody; rabbit anti-AMPKa antibody; rabbit anti-phospho-
ACC (Ser79) antibody; rabbit anti-ACC antibody; rabbit anti-phospho
mTORC1 (Ser2448) antibody; rabbit anti-mTORC1 antibody; rabbit
anti-phospho-p70 S6K (Thr389) antibody; rabbit anti-p70 S6K anti-
body; rabbit anti-phospho-AKT (Ser473) antibody; rabbit anti-AKT
antibody; rabbit anti-LC3A/B antibody; rabbit anti-GAPDH antibody
(all from Cell Signaling Technology) and mouse anti-actin antibody
(Abcam). After washing with TBS-T, membranes were incubated
with the secondary IgG anti-Rabbit antibody (Cell Signaling Technol-
ogy), at 1:5000 in 1% skim milk for 1 hour 20 minutes at room
temperature. Protein levels were detected after incubation with Clar-
ity Western ECL Substrate (Bio-Rad) or SuperSignal West Femto
Maximum Sensitivity Substrate (Thermo Scientific). Digital images
were obtained in the ChemiDoc XRS System (Bio-Rad) with the
Quantity One software (Bio-Rad). At least, 3 independent biological
replicates were performed.
2.7 | Immunofluorescence assay
After 24 hours of culture, NB-4, HL-60 and KG-1 cells (50 000
cells/plate) were re-suspended in PBS and fixed in a slide using the
cytospin technique. Fixation was then performed in 2%
paraformaldehyde (PFA). Cells were washed, permeabilized and
blocked with 4% BSA in PBS 0.05% Tween. Incubation with primary
antibody, rabbit anti-mouse LC3 A/B (Cell-Signaling), was per-
formed overnight at 4°C. Goat anti-rabbit IgG Alexa Fluor 588—
red-fluorescent dye—(Molecular Probes) was used for 1 hour as
secondary antibody. Cells were also stained with DAPI (40,6-diami-
dino-2-phenylindole) that binds to DNA regions, marking the cell
nuclei. An epifluorescence microscope (BX61 microscope with an
Olympus DP70 camera) was used to slide visualization, and images
were analysed with ImageJ Software (National Institutes of Health).
At least, 3 independent biological replicates were performed.
2.8 | Statistical analysis
All data are reported as the mean  standard error of the mean
(SEM). Statistical analysis was performed using the 2-away ANOVA
and Bonferroni’s post hoc tests to denote significant differences
between the tested groups for the annexin V/PI approach. Student’s
t test was applied to compare the extracellular glucose and lactate
levels between untreated and MK-2206 treated HL-60 and NB-4
cells. The one-way ANOVA and Tukey’s post hoc tests were used to
compare the tested groups for all the other approaches. A P-value
lower than 0.05 was assumed to denote a significant difference.
3 | RESULTS
3.1 | Glycolytic versus oxidative metabolism of
AML cells
Metabolic reprogramming, the switch from oxidative to glycolytic
metabolism, ensures a rapid production of ATP and biosynthetic pre-
cursors that confer adaptive advantages and long-term maintenance
to cancer cells.10,35 Although enhanced glucose metabolism was
recently described in AML,12,13 the association between the altered
energetic metabolism and the pathogenesis of different AML cells
remains largely unclear. Results herein presented showed that not all
AML cells prefer a glycolytic metabolism, as revealed by the quantifi-
cation of extracellular glucose and lactate levels. NB-4 cells showed
lower extracellular glucose levels associated with higher extracellular
lactate concentration when compared to HL-60 and KG-1 cells
(Figure 1A,B) indicating a higher glucose consumption and lactate
production. In contrast, KG-1 cells exhibited lower glucose uptake
and lactate release in comparison with NB-4 and HL-60 cells
(Figure 1A,B). Thus, the tested AML cells can be sorted from a prefer-
ential glycolytic metabolism, displayed by NB-4 cells, to a high oxida-
tive metabolism, presented by KG-1 cells, assuming HL-60 cells an
intermediate position. This AML glycolytic dependence is also sup-
ported by the ratio of [Lactate]/[Glucose], which was clearly higher for
NB-4 cells followed by HL-60 and KG-1 cells (Figure 1C). Consistently,
data showed NB-4 cells as those exhibiting the highest intracellular
ATP levels followed by HL-60 and KG-1 cells (Figure 1D), in agree-
ment with the production of ATP by time unit as result of their gly-
colytic rates (Figure 1A-C). To further confirm the distinct energetic
metabolism, AML cells were exposed to 2-deoxy-d-glucose (2-DG), a
synthetic glucose analogue that cannot undergo glycolysis.36 Results
demonstrated a drastic reduction in NB-4 and HL-60 cell’s viability
with no major impact on the survival of KG-1 cells, as revealed by the
annexin V/PI assay (Figure 1E). This high sensitivity of NB-4 and
HL-60 cells to the glycolytic inhibitor 2-DG further supports the gly-
colytic requirements of these cells (Figure 1A-C). Overall, these results
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showed that the tested AML cells display a distinct energetic metabo-
lism, with NB-4 and HL-60 cells being highly dependent on the gly-
colytic metabolism while KG-1 cells appear to be more dependent on
OXPHOS metabolism.
3.2 | Complexity of the mTORC1 activation
network and autophagy regulation in AML cells
The reprogramming of energetic metabolism in tumour cells is
mainly driven by the deregulation of the nutrient-sensing path-
ways.14 The occurrence of mTORC1 constitutive activation inde-
pendent of PI3K/AKT and the additional possibility of AMPK
activation illustrates the complexity of the interactions between
the nutrient-sensing pathways in the AML context (reviewed in
Ref15,37). To explore the crosstalk between the observed energetic
metabolism and the activation pattern of the nutrient-sensing path-
ways, the activation of AKT, mTORC1 and AMPK was evaluated in
AML cells. Immunoblotting analysis demonstrated a clear AKT acti-
vation in NB-4 and HL-60 cells, as reflected by the elevated levels
of phosphorylated AKT (Figure 2A). In contrast, KG-1 cells dis-
played an evident constitutive co-activation of AMPK and
mTORC1, as noticed by the highest phosphorylated levels of AMPK
and acetyl-CoA carboxylase (ACC), an AMPK direct downstream
target,38 and the increased phosphorylated levels of mTORC1 and
S6K, a direct mTORC1 downstream target39 (Figure 2B-E). Data
concerning AMPK activation agreed with the detected intracellular
ATP levels (Figure 1D), as AMPK activation occurs in the context
of energy stress (high AMP/ATP ratio)40 and KG-1 cells were those
displaying the lowest intracellular ATP levels (Figure 1D). Knowing
that AMPK may directly inhibit mTORC1 activity,41 the concomi-
tant AMPK and mTORC1 activation appears to indicate a dissocia-
tive AMPK-mTORC1 axis in KG-1 cells.
The orchestrated metabolic network perpetuated by the nutri-
ent-sensing pathways converges on the control of cellular catabolic
processes required to maintain cellular homeostasis, such as autop-
hagy.42 Given the central, although controversial, role of autophagy
in the AML pathogenesis,33,43 it is critical to comprehend not only
its regulation but also its crosstalk with the metabolic signals.
F IGURE 1 NB-4 cells present a high glycolytic metabolism followed by HL-60 and KG-1 cells. NB-4, HL-60 and KG-1 cells were
maintained for 24 h in normal growth medium. (A) Extracellular glucose and (B) lactate levels were determined using glucose and lactate
enzymatic detection kits. (C) The ratio between the extracellular lactate and glucose levels ([Lactate]/[Glucose]) was calculated. (D) Intracellular
ATP levels were assessed by the ENLITEN ATP Assay System. (E) Cell viability quantification was determined by flow cytometry analysis of
annexin V and propidium iodide (PI)-stained NB-4, HL-60 or KG-1 cells untreated or treated with 2-DG instead of glucose, for 24 h. The
results presented as mean  SEM of, at least, 3 independent biological replicates. One-way ANOVA and Tukey’s post hoc test were used to
compare the extracellular glucose and lactate levels, the [Lactate]/[Glucose] ratio and the intracellular ATP levels between NB-4, HL60 and
KG-1 cells. Annexin V/PI data were analysed using 2-way ANOVA and Bonferroni’s post hoc test. *P < .05; **P < .01; ***P < .001
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Therefore, autophagy was evaluated in the AML cells by
immunoblotting analysis of the Atg5-Atg12 complex, LC3 processing
(I and II) and LC3 puncta.44 KG-1 cells presented the highest Atg5-
Atg12 complex protein levels (Figure 3A) associated with the highest
autophagy flux, as reflected by the LC3 processing (Figure 3B).
Immunoblotting results of the LC3 processing were corroborated by
the immunostaining of LC3 showing higher number of LC3 puncta in
KG-1 cells than in NB-4 and HL-60 cells (Figure 3C), which strength-
ens our hypothesis that autophagy is up-regulated in KG-1 cells.
Overall, the data herein presented showed a mTORC1 activation
in all tested AML cells, whereas AKT activation was mainly observed
in NB-4 and HL-60 cells. Importantly, our data strongly suggest that
AMPK and mTORC1 are constitutively activated in KG-1 cells. This
distinct nutrient-sensing pathway activation profile is associated with
F IGURE 2 NB-4 and HL-60 cells exhibit AKT activation while KG-1 cells display a constitutive AMPK and mTORC1 co-activation. NB-4,
HL-60 and KG-1 cells were maintained for 24 h in normal growth medium. (A) Activation of AKT was determined by immunoblotting analysis
of phosphorylated (Ser473) AKT levels. Activation of (B) mTORC1 and (C) S6K was also assessed by immunoblotting analysis of
phosphorylated (Ser2448) mTORC1 and phosphorylated (Thr389) S6K levels, respectively. Activation of (D) AMPK and (E) ACC was evaluated
by immunoblotting analysis of phosphorylated (Thr172) AMPK and phosphorylated (Ser79) ACC levels, respectively. Actin was used as loading
control. Densitometric analysis was performed, and bands were quantified using the ImageLab4.1TM software. The results presented as
mean  SEM of, at least, 3 independent biological replicates. One-way ANOVA and Tukey’s post hoc test were used to compare the
densitometric analysis of pAKT/AKT, pmTORC1/mTORC1, pS6K/S6K, pAMPK/AMPK and pACC/ACC ratios between NB-4, HL-60 and KG-1
cells. *P < .05; ***P < .001
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an up-regulation of autophagy in KG-1 cells independently of
mTORC1.
3.3 | Manipulation of nutrient-sensing pathways
impacts on autophagy and energetic metabolism of
AML cells
Data described above suggest an AKT activation associated with a
decreased autophagy flux in NB-4 and HL-60 cells, pointing to AKT/
mTORC1 as the major regulator of autophagy in these cells. To bet-
ter understand this metabolic coordination and regulation, NB-4 and
HL-60 cells were treated with the AKT inhibitor MK-2206. As
expected, MK-2206 promoted a clear reduction of AKT and
mTORC1 (assessed by the S6K phosphorylated levels) activation
with a concomitant increase of autophagy flux (Figure 4A,B), ascrib-
ing to the AKT-mTORC1 axis a key role on the autophagy regulation
of NB-4 and HL-60 cells. On the other hand, to decipher the
relevance of the AMPK-mTORC1 axis in KG-1 cells, an AMPK inhibi-
tor, compound C (CC), or a mTORC1 inhibitor, rapamycin (Rap), were
used. Results presented in Figure 4C showed that CC promoted a
reduction in the AMPK activation with no major impact on the
mTORC1 activity (detected by the S6K phosphorylated levels), which
was accompanied by a significant decline on the autophagy flux
(Figure 4C). These data favour, once again, a dissociation of the
AMPK-mTORC1 axis and reinforce AMPK as the major regulator of
autophagy in KG-1 cells. As expected, Rap treatment induced a clear
inhibition of mTORC1 activity with a further increase of autophagy
flux (Figure 4C), suggesting that although AMPK is the main autop-
hagy regulator in KG-1 cells, mTORC1 is still able, to some extent,
to negatively control autophagy. Overall, results point to a similar
metabolic profile of NB-4 and HL-60 cells indicating the AKT-
mTORC1 axis as the major negative regulator of autophagy in these
cells, in contrast to KG-1 cells, in which autophagy is positively con-
trolled by AMPK.
F IGURE 3 NB-4 and HL-60 cells show decreased autophagy flux when compared to KG-1 cells. Autophagy flux was assessed by
immunoblotting analysis of (A) Atg5-Atg12 complex and (B) LC3 processing (I and II; all samples were incubated for 2 h with bafilomycin A1
[10 nmol/L] before the end of the experiment to block autophagy flux and to allow LC3-II accumulation) of NB-4, HL-60 and KG-1 cells
incubated for 24 h in normal growth medium. Actin was used as loading control. Densitometric analysis was performed, and bands were
quantified using the ImageLab4.1TM software. The results presented as mean  SEM of, at least, 3 independent biological replicates. One-way
ANOVA and Tukey’s post hoc test were used to compare densitometric analysis of Atg5-Atg12/Actin, LC3-II/Actin and p62/Actin ratios
between NB-4, HL60 and KG-1 cells. *P < .05; **P < .01; ***P < .001. (C) LC3 A/B-I/II puncta levels of AML cells were also assessed by
immunofluorescence assay upon 24 h in normal growth medium. NB-4, HL-60 and KG-1 cells were staining with goat LC3 anti-Rabbit IgG
antibody (red fluorescence) and samples were counter-stained with the DNA dye DAPI (blue fluorescence). Representative images of
immunofluorescence assay are presented. Bar = 20 lm
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The impact of the nutrient-sensing pathways inhibition on the
energetic metabolism of AML cells was also assessed. Inhibition of
AKT by MK-2206 resulted in a significant increase in the extracellu-
lar glucose levels associated with an evident decrease in the extra-
cellular lactate concentration of NB-4 and HL-60 cells (Figure 4D,E,
G,H), suggesting a decrease in the glucose consumption and lactate
production of these cells. Indeed, the observed decreased glycolytic
metabolism promoted by MK-2206 in the NB-4 and HL-60 cells was
confirmed by the [Lactate]/[Glucose] ratio (Figure 4J,K). These
results point to AKT as a main player on the regulation of the gly-
colytic metabolism of NB-4 and HL-60 cells. Treatment of KG-1 cells
with CC or Rap resulted in increased extracellular glucose levels and
no major alterations in the extracellular lactate concentration (Fig-
ure 4F,I,L). The maintenance of lactate concentration with decreased
glucose consumption suggests a glucose-independent source of lac-
tate and is compatible with the predominant OXPHOS metabolism
displayed by these cells (Figure 1).
In summary, the results obtained in this study indicate the funda-
mental role of AKT in controlling glycolysis of both NB-4 and HL-60
cells while supporting the low relevance of glycolysis in the KG-1
cells’ metabolism. Furthermore, the results herein presented show,
for the first time, a relation ship between energetic metabolism and
autophagy, both controlled by nutrient-sensing pathways.
3.4 | Targeting nutrient-sensing pathways sensitizes
NB-4 and HL-60 but has a minor impact on KG-1
cells
The impact of manipulating AKT, mTORC1 and AMPK on the sur-
vival of AML cells is still controversial.18,20,21,43,45 Knowing that inhi-
bition of these nutrient-sensing pathways has a major impact on
autophagy and energetic metabolism of AML cells, the viability of
these cells was evaluated. Data showed a significant decrease on the
viability of NB-4 (Figure 4M) and HL-60 (Figure 4N) cells upon
exposure to MK-2206, pointing to AKT as critical for the survival of
both types of AML cells. Given that AKT inhibition resulted in an
increase of autophagy flux in both NB-4 and HL-60 cells (Figure 4A,
B), the MK-2206-promoted cell death is associated with autophagy,
implicating autophagy as an anti-tumoural process in NB-4 and HL-
60 cells. Treatment of KG-1 cells with CC or Rap resulted in a mod-
est, although significant, decrease in their viability (Figure 4O).
Together with the distinct effects that these compounds had on
autophagy flux (Figure 4C) and with the independency of glycolysis
(Figure 1), AMPK and mTORC1 do not seem to be an attractive tar-
get for KG-1 cells. Most probably this phenomenon reflects the con-
flicting metabolic signals resulting in the constitutive co-activation of
AMPK and mTORC1.
4 | DISCUSSION
The genetic and epigenetic heterogeneity, compromising differentia-
tion, proliferation and self-renewal of hematopoietic stem cells and
myeloid progenitors, is a fundamental property of AML. This multi-
tude of AML scenarios not only has hampering the understanding of
AML’s pathogenesis and classification but also the development of
efficient therapeutic approaches. Different studies have been trying
to establish a metabolic signature of AML cells12,13,46,47; however,
the heterogeneous nature of this group of disorders has been
responsible for the current controversial literature either using cell
line models or patient’s derived samples, as primary cells or serum.
Herein, we used 3 different AML cell line models, namely the KG-1
leukaemia cell line derived from a patient with erythroleukaemia,
NB-4 a model of acute promyelocytic leukaemia (patient in second
relapse) and HL-60 a M2-derived cell line. These cell lines were cho-
sen because they are very well characterized and widely used as
representative of different AML subtypes. Using the 3 different AML
cell line models, we highlight the multitude of metabolic cellular sce-
narios that might arise even in very closely related cell lines such as
NB-4 and HL-60 cells that belong to a different genetic cluster when
compared to KG-1 cells.48
Regarding the energetic metabolism, our results categorize the
different AML cells with NB-4 as a glycolytic cell line, as reported in
some studies,49-51 HL-60 cells mainly dependent on glycolysis12 and
KG-1 cells displaying a predominant OXPHOS metabolism. These
results not only showed that 2 closely related cell lines, NB-4 and
HL-60, present different energetic metabolism, but also that KG-1
cells are mainly OXPHOS dependent, as reflected by the carbon flux
through mitochondria for lactate production (Figure 1). These data
suggest that there is no specific metabolic profile associated with
AML tumorigenesis and that different metabolic frames can sustain
AML cells’ survival and proliferation.
Altered metabolism is a direct response to growth factor sig-
nalling and to nutrient-sensing pathways such as AMPK, mTORC1
and PI3K/AKT. The data herein presented also show a correlation
between a predominant glycolytic metabolism of AML cells and acti-
vation of AKT in NB-4 and HL-60 cells, in agreement with previous
observations showing that AKT promotes glycolysis in U937 AML
cells.19 Furthermore, the AKT activation exhibited by NB-4 and HL-
60 cells (Figure 2A) is associated with reduced autophagy flux, indi-
cating that PI3K/AKT/mTORC1 activation seems to drive anabolic
metabolism and tumorigenesis in certain AML scenarios by impacting
on autophagy.
KG-1 cells displayed a completely distinct metabolic profile with
a major dependency of OXPHOS metabolism and carbon flux
through Krebs cycle. Remarkable, in KG-1 cells, a constitutive co-
activation of AMPK and mTORC1, often perceived as antagonists, is
observed. The opposite role of AMPK and mTORC1 on metabolic
reprogramming is supported by studies showing that AMPK is an
inducer of OXPHOS in T cell acute lymphoblastic leukaemia52 and
mTORC1 a promoter of the glycolytic metabolism in several AML
cell lines and human primary AML samples.18 Accordingly, our data
point to AMPK as the potential responsible for the increased oxida-
tive metabolism exhibited by KG-1 cells (Figure 1) imposing its
action to mTORC1. A similar contradictory metabolic scenario was
already reported in myoblasts in response to amino acids.53 The
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authors proposed that the concurrent activation of AMPK and
mTORC1 is implicated in the maintenance of protein homoeostasis
and on the fuel of metabolites for biosynthetic processes.53 The rel-
evance of amino acid signalling and mTORC1 PI3K/AKT-indepen-
dent activation in the context of AML remains to be explored. To
the best of our knowledge, this is the first time that the mechanism
of AMPK and mTORC1 constitutive co-activation is described in
KG-1 cells, which deserves future exploration in the regulation of
AML cells metabolism.
The novel observation of a constitutive co-activation of AMPK
and mTORC1 in KG-1 cells (Figure 2B-E) associated with increased
autophagy (Figure 3) is striking. Knowing that AMPK can induce
autophagy in mTORC1-independent pathways27-29 and that
mTORC1 is a negative regulator of autophagy,29 the obtained data
suggest a dissociative AMPK-mTORC1 axis with AMPK sustaining
autophagy in KG-1 cells. In fact, the reports of Sujobert et al and
Pezze et al also showed a direct induction of autophagy by AMPK
even in the presence of mTORC1 activation.21,53
Using human AML bone marrow mononuclear cells and an
AML mouse model, Watson et al54 showed that autophagy limits
glycolytic metabolism in the AML context. Our data show that
increased glycolytic dependence is associated with a reduced
autophagy flux (Figure 3), while a diminished glycolytic metabo-
lism, as observed in KG-1 cells (Figure 1), was accompanied by ele-
vated autophagy flux (Figure 3). These findings highlight the
contribution of autophagy in the regulation of energetic metabo-
lism, indicating an autophagy role in the control of the glycolytic
metabolism of the different tested AML cells. Our findings sug-
gesting that activated AMPK-autophagy axis is responsible for the
augmented oxidative metabolism displayed by KG-1 cells are in
agreement with data obtained in T-ALL cells and with mixed line-
age AML model.52,54 Furthermore, these studies suggest that the
complex nutrient-sensing network regulating autophagy can have a
major impact on AML pathogenesis and response to therapy,
including combined therapy with inhibitors of mTOR.
Overall the data presented on the inhibition of nutrient-sen-
sing pathways and its impact on the AML cells’ survival demon-
strate that targeting nutrient-sensing pathways sensitizes NB-4
and HL-60 cells to chemotherapy but has a minor impact on KG-
1 cells survival, which emphasizes the idea that nutrient-sensing
pathways may not constitute a promising and effective therapeutic
target.
In the present study, our results show that different AML cells
have different energetic, metabolic and autophagy patterns that
are tightly interconnected in the regulation of AML cells’ survival.
Our data also point to AKT as the major regulator of energetic
metabolism and autophagy in NB-4 and HL-60 cells. In KG-1 cells,
the energetic metabolism and autophagy seem to be regulated by
AMPK and mTORC1. These results highlight that the genetically,
metabolically and clinically heterogeneity of AML should be consid-
ered and might justify the general modest growth-inhibitory effects
in preclinical AML models and clinical trials of mTOR inhibi-
tion.25,55 Furthermore, the results highlight the relevance that com-
parative studies implying AML cell lines have on the determination
of the anti-leukaemia efficacy, particularly, of the effectiveness of
combinatory therapy with conventional and new targeted agents.
The therapeutic approach to AML diseases must pass through per-
sonalized therapy adapted to the heterogeneity of this group of
neoplasms.
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F IGURE 4 Autophagy and energetic metabolism are mainly regulated by AKT-mTORC1 axis in NB-4 and HL-60 cells and by AMPK in KG-
1 cells. NB-4 and HL-60 cells were maintained for 24 h with or without MK-2206 20 lmol/L while KG-1 cells were cultured for 24 h with or
without compound C (CC) 2.5 lmol/L or rapamycin (Rap) 2 lmol/L. (A-C) Activation of AMPK, AKT and S6K as well as autophagy flux were
assessed by immunoblotting analysis. Activation of AMPK and AKT was evaluated by immunoblotting analysis of phosphorylated (Thr172)
AMPK and phosphorylated (Ser473) AKT levels, respectively. Activation of S6K was also evaluated by immunoblotting analysis of
phosphorylated (Thr389) S6K levels. Autophagy flux was assessed by immunoblotting analysis of LC3 processing (I and II; all samples were
incubated for 2 h with bafilomycin A1 [10 nmol/L] before the end of the experiment to block autophagy flux and to allow LC3-II
accumulation). GAPDH was used as loading control. The results are representative of, at least, 3 independent biological replicates. (D-F)
Extracellular glucose and (G-I) lactate levels were determined using glucose and lactate enzymatic detection kits. (J-L) Ratio between the
extracellular lactate and glucose levels ([Lactate]/[Glucose]). The results presented as mean  SEM of, at least, 3 independent biological
replicates. Student’s t test was applied to compare the extracellular glucose and lactate levels as well as the [Lactate]/[Glucose] ratio between
untreated and MK-2206-treated NB-4 and HL-60 cells. One-way ANOVA and Tukey’s post hoc test were used to compare the extracellular
glucose and lactate levels as well as the [Lactate]/[Glucose] ratio between untreated and CC- or Rap-treated KG-1 cells. *P < .05; **P < .01;
***P < .001. (M-O) Cell viability quantification was determined by flow cytometry analysis of annexin V and PI-stained NB-4, HL-60 or KG-1
cells. The results presented as mean  SEM of, at least, 3 independent biological replicates. Annexin V/PI data were analysed using the 2-way
ANOVA and Bonferroni’s post hoc test. **P < .01; ***P < .001
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